Multi-Objective Engineering of Fibrin-Selective Thrombolytic Proteases with Enhanced Biocatalytic Efficiency and Inhibition Resistance

This study presents a multi-objective engineering framework that successfully designed Brnoteplase, a next-generation thrombolytic protease with enhanced fibrin selectivity, inhibition resistance, and catalytic efficiency, demonstrating superior therapeutic efficacy and safety in vivo compared to current FDA-approved variants.

The Gist

Imagine your body's blood vessels are like a busy highway system. Sometimes, a massive traffic jam (a blood clot) blocks the road, stopping traffic completely. This is what happens during a stroke. To fix this, doctors use "road crews" called thrombolytic enzymes (like Alteplase or Tenecteplase) that dissolve the clot and clear the path.

However, the current road crews have some problems:

1. They are slow: They don't work fast enough to clear the jam before damage is done.
2. They are clumsy: They sometimes start dissolving the wrong things (like healthy blood vessels), causing dangerous leaks (bleeding).
3. They get tired quickly: The body's security guards (inhibitors) shut them down before they can finish the job.
4. They can't get deep: They tend to stay on the surface of the clot, eating away at the outside while the core remains stuck.

This paper introduces a brand new, super-charged road crew called Brnoteplase. The scientists didn't just guess how to make it better; they used a "multi-objective engineering" strategy, which is like a high-tech recipe for building the perfect enzyme.

The "Recipe" for Brnoteplase

The scientists used three different cooking methods to find the best ingredients:

1. The Computer Chef (Rational Design): They used supercomputers to look at the blueprint of the old enzymes and figure out exactly which "screws" (amino acids) to tighten or loosen to make them faster and safer. They specifically removed parts that made the enzyme stick to the wrong places in the brain or get caught by the body's security guards.
2. The Time Traveler (Ancestral Reconstruction): They looked at the "family tree" of these enzymes, going back thousands of years to find ancient, robust versions that were naturally tougher and more stable.
3. The Treasure Hunter (Database Mining): They searched through millions of genetic sequences from nature (like bats and monkeys) to find natural variations that might have hidden superpowers.

They mixed the best parts from all these methods to create Brnoteplase.

Why Brnoteplase is a Game-Changer

Here is how Brnoteplase compares to the old crews, using some everyday analogies:

• The "Smart Bomb" vs. The "Carpet Bomb" (Fibrin Selectivity):

  • Old Enzymes: Like a carpet bomb that drops explosives everywhere, risking damage to the surrounding neighborhood (healthy tissue).
  • Brnoteplase: Like a smart missile with a laser guide. It only targets the clot (the "bad guys") and ignores everything else. The paper found it is 80 times more precise than the current standard. This means less bleeding and fewer side effects.

• The "Bulletproof Vest" (Inhibition Resistance):

  • Old Enzymes: Like a worker without armor. The body's security guards (PAI-1) can easily grab them and stop them from working, so they die out quickly.
  • Brnoteplase: Wears a bulletproof vest. It can withstand the body's security guards for much longer. This gives it a longer "shift," allowing doctors to give it as a single shot (bolus) instead of a long, slow drip (infusion).

• The "Deep Diver" (Clot Penetration):

  • Old Enzymes: Like a person trying to eat a giant cake only from the outside. They dissolve the surface, but the middle stays hard.
  • Brnoteplase: Like a deep-diving submarine. It can swim inside the clot and dissolve it from the middle out. This clears the blockage much faster and more completely.

The Results: A Safer, Faster Rescue

The scientists tested Brnoteplase in the lab and in rat models (simulating a human stroke). The results were impressive:

• It worked faster: It cleared clots more quickly than the current drugs.
• It was safer: Even at higher doses, it caused less severe bleeding in the brain compared to the old drugs.
• It lasted longer: It stayed active in the blood much longer, proving it could be given as a simple injection.

The Big Picture

This paper isn't just about one new drug; it's about a new way of thinking. Instead of trying to fix one problem at a time (like making it faster but accidentally making it dangerous), the scientists used a "multi-objective" approach. They optimized for speed, safety, and durability all at once.

Think of it like designing a new car. Instead of just making the engine faster (which might make the car crash), they redesigned the whole vehicle to be faster, safer, and more fuel-efficient simultaneously. Brnoteplase is the prototype of this new generation of medical tools, offering hope for a future where strokes can be treated with a single, safe, and highly effective shot.

Technical Summary

1. Problem Statement

Current thrombolytic enzymes used for treating acute ischemic stroke, such as alteplase and tenecteplase, face significant clinical limitations:

• Suboptimal Catalytic Efficiency: Low recanalization rates (<50% for alteplase).
• Short Biological Half-life: Rapid clearance from the bloodstream necessitates continuous infusion rather than bolus administration.
• Off-Target Activity: Non-specific activation of plasminogen leads to systemic plasminemia, increasing the risk of intracranial hemorrhage (ICH).
• Susceptibility to Inhibition: Rapid inactivation by Plasminogen Activator Inhibitor-1 (PAI-1).
• Neurotoxicity: Binding to receptors like LRP1 (Low-Density Lipoprotein Receptor-Related Protein 1) and NMDAR (N-methyl-D-aspartate receptor) contributes to neurotoxicity and rapid clearance.

The core challenge is a multi-objective optimization problem: improving one property (e.g., fibrin specificity) often compromises another (e.g., catalytic activity or stability). Existing engineering approaches have failed to simultaneously optimize all critical parameters required for a superior therapeutic profile.

2. Methodology

The authors developed a comprehensive multi-objective enzyme engineering workflow that integrates computational design with hierarchical experimental validation. The pipeline screened over 10,000 variants down to a single lead candidate.

A. Computational Design Strategies

Three complementary in silico approaches were used to generate a pool of candidate variants based on the alteplase scaffold:

1. Rational Design (Structure & Sequence-Based):
   • LRP1 Binding Reduction: Identified lysine residues on the first four domains of alteplase responsible for LRP1 binding. Mutations (e.g., K10E, K49I, K152Q, K82A, K159S, K162I) were designed using molecular dynamics and docking to disrupt this interaction.
   • NMDAR & Glycosylation: Introduced mutations (e.g., W253R, N117Q) to reduce neurotoxicity and remove high-mannose glycosylation sites responsible for rapid clearance.
   • PAI-1 Resistance & Fibrin Specificity: Combined mutations known to reduce PAI-1 inhibition (K296A, H297A, R298A, R299A) and enhance fibrin specificity.
2. Ancestral Sequence Reconstruction (ASR): Used the FireProtASR server to reconstruct evolutionary ancestors of alteplase to access robust, naturally optimized scaffolds.
3. Database Mining: Used EnzymeMiner to search protein databases for homologs of alteplase and desmoteplase (a highly fibrin-selective enzyme from vampire bats) with favorable predicted properties (solubility, lack of transmembrane regions).

B. Experimental Workflow

1. Production: 11 selected variants were expressed in HEK-293E cells.
2. Biochemical Characterization:
   • Thermal Stability: Measured via nanoDSF.
   • Activity & Selectivity: Assessed using fluorogenic substrates with and without fibrin/fibrinogen stimulation to calculate fibrin selectivity ($Sel_{FN}$).
   • Inhibition Resistance: Determined IC50 values against PAI-1.
   • Fibrin Binding: Measured dissociation constants ($K_d$) to assess penetration potential.
3. In Vitro Validation:
   • Thrombolysis: Tested on semi-synthetic and RBC-dominant clots in static and flow models.
   • Penetration: Used fluorescently labeled proteins in fibrin gel microarrays to measure penetration depth and rate.
4. In Vivo Validation (Rat Models):
   • Efficacy Study: Artificial clots injected into the aortic arch of Wistar rats. Measured lysis rates and Area Under the Curve (AUC) via micro-fluoroscopy.
   • Safety Study: Thromboembolic Middle Cerebral Artery Occlusion (MCAO) model. Evaluated Hemorrhagic Transformation (HT) severity (ECASS II criteria) and hemispheric asymmetry (brain swelling) via micro-CT.

3. Key Contributions

• Development of Brnoteplase: The identification of a lead variant, Brnoteplase, which combines mutations from rational design (reducing LRP1/NMDAR binding, increasing PAI-1 resistance) and ancestral reconstruction.
• Multi-Objective Framework: A validated pipeline that successfully navigates trade-offs between catalytic efficiency, selectivity, stability, and safety, moving beyond single-parameter optimization.
• Mechanistic Insight: Demonstrated that reducing fibrin binding affinity (to improve penetration) and increasing PAI-1 resistance can be achieved simultaneously without sacrificing catalytic activity on the clot surface.

4. Key Results

Biochemical Properties

• Fibrin Selectivity: Brnoteplase exhibited an extraordinary fibrin selectivity of 1020 ± 360, which is 80-fold higher than alteplase (13.5) and comparable to tenecteplase and desmoteplase.
• Inhibition Resistance: Brnoteplase showed 4-fold higher resistance to PAI-1 inhibition compared to alteplase.
• Penetration Potential: It demonstrated a 4-fold lower fibrin binding affinity ($K_d$), suggesting superior ability to penetrate deep into clots rather than binding only to the surface.
• Stability: Retained activity after 3 months of storage at +4°C, unlike alteplase which showed degradation.

In Vitro Performance

• Concentration Dependence: Unlike alteplase, which showed a plateau or decline in efficacy at high concentrations, Brnoteplase showed a dose-dependent increase in thrombolytic efficacy, surpassing alteplase at high doses (65 µg/mL).
• Penetration: In fibrin gel assays, Brnoteplase penetrated significantly deeper (>0.75 mm) than alteplase, enabling lysis from within the clot.

In Vivo Performance (Rat Models)

• Efficacy: Brnoteplase (administered as a bolus) achieved a lysis rate of 1.3 ± 0.4 %/min, significantly higher than alteplase (0.9 ± 0.5 %/min, continuous infusion) and tenecteplase (1.1 ± 0.5 %/min).
• Pharmacokinetics: Residual active Brnoteplase levels in plasma were 30–37 times higher than alteplase, confirming an extended biological half-life that supports bolus administration.
• Safety:
  • Hemorrhagic Transformation (HT): While Brnoteplase had a high overall HT incidence (86%, indicating high recanalization), the severity was significantly lower. 60% of cases were mild petechial hemorrhages (HI1), compared to only 24% for tenecteplase and 43% for alteplase. Severe hemorrhages (PH1/PH2) were rare.
  • Brain Swelling: Brnoteplase-treated rats showed the lowest hemispheric asymmetry (11%), indicating reduced cerebral edema compared to alteplase (15%).

5. Significance

This study presents a breakthrough in the engineering of thrombolytic biocatalysts. Brnoteplase represents a next-generation therapeutic candidate that overcomes the historical limitations of current drugs:

1. Bolus Administration: Its resistance to PAI-1 and clearance receptors allows for a single bolus injection, simplifying clinical administration compared to the 1-hour infusion required for alteplase.
2. Enhanced Safety: By minimizing off-target receptor binding and systemic plasmin generation, it reduces the risk of severe intracranial hemorrhage and neurotoxicity.
3. Superior Efficacy: Its ability to penetrate deep into clots and maintain activity at higher doses suggests it could be more effective for large or dense thrombi, potentially expanding the treatment window for stroke patients.

The authors conclude that their multi-objective engineering framework is a generalizable strategy for developing complex biological therapeutics, proving that rational design combined with evolutionary reconstruction can successfully optimize enzymes for demanding physiological environments.